chevron_leftBack
As of 17 June 2026, Elicio Therapeutics, Inc. has a market cap of $52.68M USD, ranking #30262 globally and #4433 in the United States.
It ranks #2744 in the Healthcare sector, and #531 in the Biotechnology industry.
Key Stats
Market Cap
$52.68MUSD
Enterprise Value
$186.16MUSD
EBITDA (TTM)
-$37.51MUSD
Net Income (TTM)
-$39.57MUSD
PB Ratio
117.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Connelly
open_in_new
Employees
33
Founded
2011
Website
elicio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.9% | -15% | -1.4% | 26% | 5.7% | 107% |
News
Loading...
ELTX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ELTX
Elicio Therapeutics Inc
ISIN: US28657F1030
Shares Out.:
Shares Outstanding:
19.086M1
Shares Float:
13.15M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
10.38 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
346K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
303K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
52K%
|
-
|
|
NYSE: IQV
|
$26.3B
50K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
47K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
34K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$48.06B
91K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$45.17B
86K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.62B
81K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.51B
81K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.33B
54K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
49K%
|
-
|
chevron_leftBack